Name: Amara View
Brand: Philips
SKU: HCNOCTN374

Media Gallery

Features

Innovative design: Innovative design

Amara View's innovative design prevents red marks, discomfort or irritation on the nose bridge.¹ This design gives Amara View the widest field of vision of all leading full face masks² and enables wearing glasses, reading or watching TV.
Convenient magnetic clips: Convenient magnetic clips

Magnetic clips make attaching or reattaching headgear before bed or in the middle of the night easy and fast. Availability of magnetic clips varies. Contact your local Philips customer service department for availability.
Easy to use: Easy to use

One modular frame for all cushion sizes.
Wide field of vision: Wide field of vision

Amara View covers less of the patient’s face and has a wider field of vision than the Resmed AirFit F20 or the Fisher & Paykel Simplus. It’s also smaller and lighter (Note: excludes Amara View’s quick release tube)

Innovative design
Convenient magnetic clips
Easy to use
Wide field of vision

New patients prefer Amara View nearly 4 to 1 over Quattro, based on the degree of confinement they feel wearing the masks.*

29% higher in comfort**

29% higher in seal**

20% higher in stability**

25% higher with overall fit**

37% higher in overall appeal**

Want to see more results?

Download infographic for all details

*Philips-Respironics sponsored testing at seven contracted clinical sites for a 2 week X 2 week randomized crossover study with 64 patients new to CPAP. Each patient tried Amara View and either Quattro or AirFit F10. Mask order between the two mask was randomized. Mask comparison responses were collected after the second interval crossover. Statistical significance at 95% confidence,+/- 5% using a one-sample Bionomial Test comparing the observed proportion to a 50/50 split. Average comparisons using a 0 to 10 rating score Among participants expressing a preference of one mask over another; Quattro, p-value = .004

**Philips-Respironics sponsored testing at two contracted clinical sites. Ninety-five compliant Quattro patients rated Quattro and then Amara View after approximately 30 days. Statistical significance at 95% confidence, +/- 5% using paired t-test comparing averages of 0 to 10 rating scores; p-value < .001